IL154053A0 - AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS alpha4 INTEGRIN ANTAGONISTS - Google Patents

AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS alpha4 INTEGRIN ANTAGONISTS

Info

Publication number
IL154053A0
IL154053A0 IL15405301A IL15405301A IL154053A0 IL 154053 A0 IL154053 A0 IL 154053A0 IL 15405301 A IL15405301 A IL 15405301A IL 15405301 A IL15405301 A IL 15405301A IL 154053 A0 IL154053 A0 IL 154053A0
Authority
IL
Israel
Prior art keywords
aza
bridged
amino acid
acid derivatives
integrin antagonists
Prior art date
Application number
IL15405301A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL154053A0 publication Critical patent/IL154053A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15405301A 2000-06-30 2001-06-29 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS alpha4 INTEGRIN ANTAGONISTS IL154053A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21569500P 2000-06-30 2000-06-30
US09/891,602 US6960597B2 (en) 2000-06-30 2001-06-26 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
PCT/US2001/020857 WO2002002556A2 (en) 2000-06-30 2001-06-29 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS

Publications (1)

Publication Number Publication Date
IL154053A0 true IL154053A0 (en) 2003-07-31

Family

ID=26910288

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15405301A IL154053A0 (en) 2000-06-30 2001-06-29 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS alpha4 INTEGRIN ANTAGONISTS

Country Status (19)

Country Link
US (1) US6960597B2 (pl)
EP (1) EP1303492A2 (pl)
JP (1) JP2004506612A (pl)
KR (1) KR20030014287A (pl)
CN (1) CN1449385A (pl)
AR (1) AR031853A1 (pl)
AU (1) AU2001273095A1 (pl)
BR (1) BR0112359A (pl)
CA (1) CA2415088A1 (pl)
HK (1) HK1052343A1 (pl)
HU (1) HUP0301195A2 (pl)
IL (1) IL154053A0 (pl)
MX (1) MXPA03000814A (pl)
NO (1) NO20026252L (pl)
NZ (1) NZ523852A (pl)
PL (1) PL359997A1 (pl)
RU (1) RU2003102631A (pl)
WO (1) WO2002002556A2 (pl)
YU (1) YU98902A (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
PL223152B1 (pl) 2000-08-18 2016-10-31 Ajinomoto Kk Pochodne fenyloalaniny, kompozycja farmaceutyczna oraz zastosowanie tych pochodnych
ATE345127T1 (de) 2000-09-29 2006-12-15 Ajinomoto Kk Neue phenylalanin-derivate
JP4336196B2 (ja) * 2001-07-18 2009-09-30 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
EP3527228A1 (en) * 2003-01-24 2019-08-21 Biogen MA Inc. Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
CN1917881B (zh) 2003-12-22 2014-11-26 味之素株式会社 新型苯基丙氨酸衍生物
JP2007522224A (ja) * 2004-02-10 2007-08-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ α４インテグリン拮抗薬としてのピリダジノン尿素
KR20070004676A (ko) * 2004-02-10 2007-01-09 얀센 파마슈티카 엔.브이. 알파４ 인테그린의 길항제로서의 피리다지논
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
US20060223846A1 (en) * 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1917253B1 (de) * 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2781390A1 (en) 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
JP6441831B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
KR102271179B1 (ko) * 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
LT3191487T (lt) 2014-09-12 2019-10-10 Boehringer Ingelheim International Gmbh Katepsino c spirocikliniai inhibitoriai
CN108431038A (zh) 2015-10-06 2018-08-21 豪夫迈·罗氏有限公司 治疗多发性硬化的方法
EP3939989A1 (en) * 2016-11-11 2022-01-19 Zealand Pharma A/S Cyclic peptides multimers targeting alpha 4beta 7 integrin
CN112969700A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
JP7189369B2 (ja) * 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
EP3873897A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
JPS6314774A (ja) 1986-07-07 1988-01-21 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827860A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5523308A (en) * 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
US6291511B1 (en) * 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
WO1999006433A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
IL133635A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
HUP0002682A3 (en) 1997-07-31 2001-12-28 American Home Products Corp Ma Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
US6455550B1 (en) * 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
ATE260243T1 (de) 1997-08-22 2004-03-15 Hoffmann La Roche N-aroylphenylalaninderivate
AU739511B2 (en) 1997-08-22 2001-10-11 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
US6229011B1 (en) * 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
AU748041B2 (en) * 1997-10-31 2002-05-30 Aventis Pharma Limited Substituted anilides
US6191171B1 (en) * 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
EP1056714B1 (en) 1998-02-26 2004-08-11 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
US6121280A (en) 1998-03-24 2000-09-19 Pfizer Inc. Azabicyclic rotomase inhibitors
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821406D0 (en) 1998-10-01 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
JP2002535304A (ja) 1999-01-22 2002-10-22 エラン ファーマシューティカルズ，インコーポレイテッド Ｖａｌ−４により媒介される白血球接着を阻害する多環式化合物
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2361479A1 (en) * 1999-01-27 2000-08-03 Ortho-Mcneil Pharmaceutical, Inc. Peptidyl heterocyclic ketones useful as tryptase inhibitors
DK1154993T3 (da) * 1999-02-18 2005-02-14 Hoffmann La Roche Thioamid-derivater
AU3246600A (en) * 1999-03-01 2000-09-21 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
AU6903200A (en) * 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
WO2001014328A2 (en) 1999-08-20 2001-03-01 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
US20030130166A1 (en) * 1999-08-24 2003-07-10 Sonia Cunningham Polynucleotide encoding a human junctional adhesion protein (JAM2)
US6469047B1 (en) 1999-09-24 2002-10-22 Genentech, Inc. Tyrosine derivatives
US6534513B1 (en) * 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
DE19950862C5 (de) 1999-10-21 2004-02-26 Lucas Varity Gmbh Betätigungseinheit für eine elektronisch gesteuerte Fahrzeugbremsanlage
WO2001032610A1 (fr) 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Derive d'uree, son procede de production, et produit pharmaceutique contenant ce derive d'uree
WO2001036376A1 (fr) 1999-11-18 2001-05-25 Ajinomoto Co., Inc. Nouveaux dérivés de la phénylalanine
SI1237878T1 (sl) 1999-12-06 2007-08-31 Hoffmann La Roche 4-pirimidinil-n-acil-l-fenilanin
BR0016172A (pt) 1999-12-06 2002-08-20 4-piridinil-n-acil-l-fenilalaninas
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) * 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US6849639B2 (en) * 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
CA2394431C (en) * 1999-12-16 2015-06-30 Jane Relton Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
CN1413210A (zh) * 1999-12-28 2003-04-23 辉瑞产品公司 用于治疗炎症、自身免疫性疾病和呼吸系统疾病的vla－4依赖性细胞结合的非肽基抑制剂
EP1253923A1 (en) 2000-01-28 2002-11-06 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
US6579889B2 (en) * 2000-06-22 2003-06-17 Merck & Co., Inc. Substituted isonipecotyl derivatives as inhibitors of cell adhesion
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US7015216B2 (en) * 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
AU2001282938A1 (en) 2000-07-21 2002-02-05 Elan Pharmaceuticals, Inc. Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by vla-4
PL223152B1 (pl) 2000-08-18 2016-10-31 Ajinomoto Kk Pochodne fenyloalaniny, kompozycja farmaceutyczna oraz zastosowanie tych pochodnych
US6709192B2 (en) 2000-09-05 2004-03-23 The Fort Miller Group, Inc. Method of forming, installing and a system for attaching a pre-fabricated pavement slab to a subbase and the pre-fabricated pavement slab so formed
KR20030036724A (ko) 2000-09-14 2003-05-09 도레이 가부시끼가이샤 우레아 유도체 및 그것을 유효성분으로 하는 접착분자저해제
GB0028844D0 (en) * 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
US6559174B2 (en) * 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
WO2003010135A1 (fr) 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Nouveaux derives de l'acide phenylpropionique

Also Published As

Publication number Publication date
AU2001273095A1 (en) 2002-01-14
EP1303492A2 (en) 2003-04-23
US20020091115A1 (en) 2002-07-11
HK1052343A1 (zh) 2004-02-06
CA2415088A1 (en) 2002-01-10
RU2003102631A (ru) 2004-09-27
NZ523852A (en) 2004-11-26
PL359997A1 (pl) 2004-09-06
YU98902A (sh) 2006-05-25
NO20026252L (no) 2003-02-26
WO2002002556A3 (en) 2002-07-18
JP2004506612A (ja) 2004-03-04
CN1449385A (zh) 2003-10-15
HUP0301195A2 (hu) 2003-08-28
US6960597B2 (en) 2005-11-01
AR031853A1 (es) 2003-10-08
BR0112359A (pt) 2003-05-27
WO2002002556A2 (en) 2002-01-10
NO20026252D0 (no) 2002-12-27
KR20030014287A (ko) 2003-02-15
MXPA03000814A (es) 2004-11-01

Similar Documents

Publication Publication Date Title
IL154053A0 (en) AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS alpha4 INTEGRIN ANTAGONISTS
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
GB0012850D0 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
EG24136A (en) Piperazine derivatives useful as ccr5 antagonists
HK1058361A1 (en) Urea derivatives as integrin alpha 4 antagonists
GB0018828D0 (en) Alkyl Amino Acid Derivatives useful as pharmaceutical agents
EP1206262A4 (en) Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES
AU3157801A (en) Beta-amino acid compounds as integrin antagonists
AU5216801A (en) Carboxylic acid derivatives as ip antagonists
IL150550A0 (en) 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
MXPA02008402A (es) Derivados de quinolina como antagonistas alfa-2.
AU2001231730A1 (en) Piperidyl carboxylic acids as integrin antagonists
AU2001234741A1 (en) Integrin antagonists
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
IL148623A0 (en) Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
AU2002220598A1 (en) Beta-amino acid derivatives as integrin receptor antagonists
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
GB0026578D0 (en) Heterocyclic derivatives useful as pharmaceutical agents
AU6221201A (en) Propanoic acid derivatives as integrin receptor antagonists
HUP0203756A3 (en) Ciclesonide-containing aqueous pharmaceutical composition
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU2001265866A1 (en) Cyclic carboxylic acids as integrin antagonists
PL358585A1 (pl) N-Podstawione pochodne kwasu 1-amino-1,1-dialkilokarboksylowego
AU2001283539A1 (en) Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
AU2001268490A1 (en) Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists